Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 45 clinical trials
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas

This is a study to determine the safety and efficacy of the drug, mebendazole, when used in combination with standard chemotherapy drugs for the treatment of pediatric brain tumors. Mebendazole is a drug used to treat infections with intestinal parasites and has a long track record of safety in humans. …

corticosteroids
low grade glioma
chemotherapeutic agents
vincristine
brainstem tumor
  • 228 views
  • 01 May, 2022
  • 1 location
GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas(DIPG) & Spinal Diffuse Midline Glioma(DMG)

pontine glioma (DIPG) or spinal H3K27M-mutant diffuse midline glioma (DMG). H3K27Mmutant testing will occur as part of standard of care prior to enrollment.

  • 3 views
  • 29 Jun, 2022
  • 1 location
Phase I Study of APX005M in Pediatric CNS Tumors

(progressive), or newly diagnosed diffuse intrinsic pontine glioma. APX005M can trigger activation of B cells, monocytes, and dendritic cells and stimulat cytokine release from lymphocytes and monocytes

nitrosourea
diffuse intrinsic pontine glioma
nitrosoureas
myelosuppressive chemotherapy
dipg
  • 167 views
  • 27 Jun, 2022
  • 11 locations
Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors (PNOC025)

intrinsic pontine glioma (DIPG), high-grade glioma (adult and pediatric), medulloblastoma, and embryonal tumors formerly called Primitive Neuro-Ectodermal Tumors (PNET). Safety studies in humans have proven

  • 0 views
  • 29 May, 2022
  • 1 location
Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors

This phase I trial studies the side effects and best dose of volitinib in treating patients with primary central nervous system (CNS) tumors that have come back (recurrent) or does not respond to treatment (refractory). Volitinib may stop the growth of tumor cells by blocking some of the enzymes needed …

  • 4 views
  • 01 Jul, 2022
  • 10 locations
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma

This phase I trial studies the side effects and best dose of pembrolizumab and to see how well it works in treating younger patients with high-grade gliomas (brain tumors that are generally expected to be fast growing and aggressive), diffuse intrinsic pontine gliomas (brain stem tumors), brain tumors with a …

diffuse intrinsic pontine glioma
absolute neutrophil count
nitrosoureas
medulloblastoma
ependymoma
  • 111 views
  • 28 Jun, 2022
  • 7 locations
Multi-antigen T Cell Infusion Against Neuro-oncologic Disease (REMIND)

blood mononuclear cells (PBMC). Group A patients (DIPG): The first TAA-T dose will be infused any time 14 days or more after completion of radiotherapy. Group B patients (other recurrent

nervous
malignant glioma
residual tumor
medulloblastoma
ependymoma
  • 4 views
  • 01 Feb, 2022
  • 1 location
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block signals passed from one …

  • 0 views
  • 01 Jul, 2022
  • 12 locations
Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma (PNOC008)

This is a 2 strata pilot trial within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). The study will use a new treatment approach based on each patient's tumor gene expression, whole-exome sequencing (WES), targeted panel profile (UCSF 500 gene panel), and RNA-Seq. The current study will test the efficacy of such …

MRI
diffuse intrinsic pontine glioma
malignant glioma
dipg
epilepsy
  • 24 views
  • 13 Mar, 2022
  • 12 locations
A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

This is a pilot study that will evaluate disease status in children that have been newly diagnosed high-grade glioma with TRK fusion. The evaluation will occur after 2 cycles of the medication (Larotrectinib) have been given. The study will also evaluate the safety of larotrectinib when given with chemotherapy in …

  • 0 views
  • 16 May, 2022
  • 6 locations